Germany Cancels Confidential Drug Pricing
Plans to make pharmaceutical prices in Germany confidential are likely to be shelved, but other measures could help companies better navigate price transparency.
You may also be interested in...
Companies might have to rethink their German market access strategies if new legislation is passed to informs doctors of the outcome of AMNOG benefit assessments.
Under forthcoming changes to the law, companies could gain confidential pricing in Germany, which could make it easier to defend a higher price in other countries. But sponsor of some orphan products may face a rockier path to market.
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.